Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

被引:2
作者
El Melegy, N. T. [1 ]
Aboulella, H. A. [2 ]
Abul-Fadl, A. M. [1 ]
Mohamed, N. A. [1 ]
机构
[1] Assiut Univ, Fac Med, Dept Biochem, Assiut, Egypt
[2] Assiut Univ, Fac Med, Dept Urol, Assiut, Egypt
关键词
N-Acetylneuraminic acid; Prostate-specific antigen; Prostatic hyperplasia; Prostatic neoplasms; SERUM SIALIC-ACID; CATHEPSIN-D; ANTIGEN RATIO; MEN; DIAGNOSIS; MARKER; LEVEL; AGE;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This study aims to evaluate the role of free/total prostate-specific antigen (PSA) ratio, serum total sialic acid level and cathepsin D activity in the differentiation of prostate cancer and benign prostatic hyperplasia (BPH). The study looked at 100 patients with BPH, 75 patients with organ-confined or locally advanced prostate cancer, and a control group of 50 healthy volunteers. Prostate cancer patients showed significantly higher total sialic acid level and cathepsin D activity and lower free/total PSA ratio than those in the BPH group. The results suggest that combined measurement of serum total sialic acid and/or cathepsin D activity with free/total PSA ratio could serve as a useful adjunct to conventional diagnostics for the differentiation of prostate cancer and BPH.
引用
收藏
页码:109 / 112
页数:4
相关论文
共 33 条
[1]   THE DISTRIBUTION OF PROSTATE SPECIFIC ANTIGEN IN MEN WITHOUT CLINICAL OR PATHOLOGICAL EVIDENCE OF PROSTATE-CANCER - RELATIONSHIP TO GLAND VOLUME AND AGE [J].
BABAIAN, RJ ;
MIYASHITA, H ;
EVANS, RB ;
RAMIREZ, EI .
JOURNAL OF UROLOGY, 1992, 147 (03) :837-840
[2]   Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: Which is clinically effective and when? [J].
Basso, D ;
Fogar, P ;
Piva, MG ;
Navaglia, F ;
Mazza, S ;
Prayer-Galetti, T ;
Castellucci, E ;
Pagano, F ;
Plebani, M .
UROLOGY, 2000, 55 (05) :710-715
[3]   New circulating biomarkers for prostate cancer [J].
Bensalah, K. ;
Lotan, Y. ;
Karam, J. A. ;
Shariat, S. F. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2008, 11 (02) :112-120
[4]  
Berbec H, 1999, EUR J GYNAECOL ONCOL, V20, P389
[5]   Analysis of cathepsin D forms and their clinical implications in human prostate cancer [J].
Cherry, JP ;
Mordente, JA ;
Chapman, JR ;
Choudhury, MS ;
Tazaki, H ;
Mallouh, C ;
Konno, S .
JOURNAL OF UROLOGY, 1998, 160 (06) :2223-2228
[6]  
de la Taille A, 1998, BRIT J UROL, V82, P389
[7]  
DIAZ MEG, 2001, ARCH ESP UROL, V54, P101
[8]   Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer [J].
Ellis, WJ ;
Etzioni, R ;
Vessella, RL ;
Hu, CC ;
Goodman, GE .
JOURNAL OF UROLOGY, 2001, 166 (01) :93-98
[9]  
ERBIL KM, 1986, CANCER-AM CANCER SOC, V57, P1389, DOI 10.1002/1097-0142(19860401)57:7<1389::AID-CNCR2820570725>3.0.CO
[10]  
2-G